Mannkind Corp
MNKD
Market Cap$1.41B
Close$
$4.94
7.5% downside
Current Fair Value
7.5% downsideOvervalued by 7.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.41 Billion |
|---|---|
| Enterprise Value | $1.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.1 |
| Beta | 1.02 |
| Outstanding Shares | 304,954,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 42.68 |
|---|---|
| PEG | -32.05 |
| Price to Sales | - |
| Price to Book Ratio | -5.34 |
| Enterprise Value to Revenue | 5.61 |
| Enterprise Value to EBIT | 20.41 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -1.05 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Mannkind Corp
233 employees
CEO: Michael Castagna MannKind Corporation focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza? (insulin human) Inhalation Powder,...